AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 294: E1097-E1108, 2008. First published April 15, 2008; doi:10.1152/ajpendo.00748.2007
0193-1849/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/6/E1097    most recent
00748.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gunawardana, S. C.
Right arrow Articles by Piston, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gunawardana, S. C.
Right arrow Articles by Piston, D. W.

Dimethyl amiloride improves glucose homeostasis in mouse models of type 2 diabetes

Subhadra C. Gunawardana, W. Steven Head, and David W. Piston

Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee

Submitted 28 November 2007 ; accepted in final form 9 April 2008

Dimethyl amiloride (DMA) enhances insulin secretion in the pancreatic β-cell. DMA also enhances time-dependent potentiation (TDP) and enables TDP to occur in situations where it is normally absent. As we have demonstrated before, these effects are mediated in part through inhibition of neuronal nitric oxide synthase (nNOS), resulting in increased availability of arginine. Thus both DMA and arginine have the potential to correct the secretory defect in diabetes by enabling or enhancing TDP. In the current study we have demonstrated the ability of these agents to improve blood glucose homeostasis in three mouse models of type 2 diabetes. The pattern of TDP under different conditions indicates that inhibition of NOS is not the only mechanism through which DMA exerts its positive effects. Thus we also have explored another possible mechanism through which DMA enables/enhances TDP, via the activation of mitochondrial {alpha}-ketoglutarate dehydrogenase.

pancreatic islets; β-cell memory; insulin secretion



Address for reprint requests and other correspondence: D. W. Piston, Dept. of Molecular Physiology and Biophysics, Vanderbilt Univ. School of Medicine, Nashville, TN 37232 (e-mail: dave.piston{at}vanderbilt.edu)




This article has been cited by other articles:


Home page
In VivoHome page
A. CHATZIGEORGIOU, A. HALAPAS, K. KALAFATAKIS, and E. KAMPER
The Use of Animal Models in the Study of Diabetes Mellitus
In Vivo, March 1, 2009; 23(2): 245 - 258.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.